Eloxx's exaluren increases kidney collagen IV in Phase 2a Alport syndrome study
ELOX•All three participants in Eloxx Pharmaceuticals' Phase 2a study showed increased kidney collagen production after eight weeks of exaluren treatment, with partially improved kidney cell structure.
1. Study results
Eloxx Pharmaceuticals published Phase 2a results for exaluren in nonsense mutation Alport syndrome. All three participants, aged 12 to 18, showed increased kidney collagen production and partially improved kidney cell structure after eight weeks of treatment. Proteinuria changes were inconsistent, and blood in the urine persisted in all participants. Exaluren was well tolerated, with no serious adverse events, kidney toxicity or hearing toxicity; the findings support the ongoing Phase 2b EXACT study.



